News & Press

Filter by year:

GeNeuro Reports 2017 Half-Year Results and Provides Corporate Update

Geneva, Switzerland, 28 September 2017 at 06:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, today reported its half-year financial results for the period ending June 30, 2017 and provided a corporate update.

GeNeuro and Servier to Present Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis at MSParis2017

Geneva, Switzerland, and Paris, France - 19 Septembre 2017 at 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today that 6-month data from the CHANGE-MS Phase 2b study will be presented at MSParis2017, the 7th Joint ECTRIMS-ACTRIMS meeting held 25-28 October 2017, in Paris, France. The presentation will cover efficacy and safety data, and will include post-hoc analyses supporting the hypothesis of a

[An ancestral retroviral protein identified as a therapeutic target in type-1 diabetes].

Levet S, Medina J, Joanou J, Demolder A, Queruel N, Réant K, Normand M, Seffals M, Dimier J, Germi R, Piofczyk T, Portoukalian J, Touraine JL, Perron H

JCI Insight. 2017;2(17):e94387. 

GeNeuro and Collaborators Publish Data Supporting Role of Retroviral Pathogenic Envelope Protein in Type 1 Diabetes (T1D)

Geneva, Switzerland, 11 September 2017 – 07:30 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that data supporting the role of pathogenic pHERV-W env in Type 1 diabetes has been published in The Journal of Clinical Investigation Insight. Pathogenic pHERV-W env is encoded by a member of the HERV-W family. HERVs are ancestral retroviral DNA insertions in the human genome, thought to account for up to 8% of the human genome.

GeNeuro and Servier Announce Six-Month Results from CHANGE-MS Phase 2b Study in Multiple Sclerosis

Geneva, Switzerland, and Paris, France, 28 August 2017 – 07:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO) and Servier announced today 6-month results from the 12-month CHANGE-MS Phase 2b study of three doses of GNbAC1 for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS).

GeNeuro updates on cash, revenue and activities at Q2 2017

Genève, Switzerland, 31 July 2017 - 6:00pm CEST : GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclerosis and type-1 diabetes, reports today on its cash and revenues for the second quarter 2017 and provides an update on its activities.

GeNeuro Announces First Patient Treated in Phase 2a Study with GNbAC1 in Type 1 Diabetes

Geneva, Switzerland, 19 June 2017 - 7:30am CEST : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that the first patient has been treated in its Australian Phase 2a study of GNbAC1 in type 1 diabetes. This is GNbAC1’s second indication after multiple sclerosis, for which an international Phase 2b study is ongoing in 260 patients.

GeNeuro Presents Data Supporting Role of Human Endogenous Retroviruses (HERVs) in Type 1 Diabetes at American Diabetes Association (ADA) Scientific Sessions

Geneva (Switzerland), 12 june 2017 - 7:30am CEST : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today data supporting the link between human endogenous retroviruses (HERVs) and Type 1 diabetes (T1D). Data were presented at the 77th Scientific Sessions of the American Diabetes Association in San Diego, USA (June 9-13, 2017).

GeNeuro Reports 2016 Full-Year Results and Provides Corporate Update

Geneva (Switzerland), April 27, 2017 : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis (MS), today reported its full-year results for the year ended December 31, 2016, and provided a corporate update.

GeNeuro Initiates Phase 2a Study with GNbAC1 in Type 1 Diabetes in Australia

Geneva (Switzerland), April 18, 2017 : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today the initiation of a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes (T1D). GNbAC1 is a monoclonal antibody designed to neutralise MSRV-Env, a pathogenic protein that has been detected in the pancreas of T1D patients.


Results 1-10 of 17      Next Page      Last Page